Palvella Therapeutics (PVLA) AI Stock Analysis

• Market Cap: $1.60B
• Dividend Yield: N/A
• Average Volume (3M): 349.64K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.01
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.03
• Shares Outstanding: 11,836,490
• 10 Day Avg. Volume: 517,807
• 30 Day Avg. Volume: 349,645
• PEG Ratio: 0.01
• Price to Book (P/B): 0.43
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.46
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -79.64
• 1Y Price Target: $214.76
• Price Target Upside: 59.06% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): -3.88
• Revenue Forecast (FY): $226.67K

• Rating: 49 Neutral
• Price Target: $78.00 ▼(-42.23% Downside)
• Action: Reiterated Date: 01/30/26
• Date: Action: Reiterated 01/30/26

The score is held down primarily by weak financial performance (no current revenue, ongoing losses, and persistent cash burn) and bearish technical signals. Offsetting this, corporate events are notably positive with encouraging Phase 2 data and clear near-term clinical/regulatory catalysts, but this does not fully overcome the current fundamentals and trend.

Positive Factors

Conservative balance sheet

Zero reported debt and materially improved equity provide durable financial flexibility for a clinical‑stage biotech. This reduces near‑term refinancing pressure, supports milestone funding for trials, and lowers bankruptcy risk compared with highly levered peers over the next 2–6 months.

Late‑stage pipeline advancement

Advancing QTORIN toward potential first‑in‑disease approvals and a Phase 3 topline in March 2026 represents a structural shift from platform development to near‑commercial execution. Successful outcomes would create durable market entry, expanded franchise opportunities, and lasting revenue streams in specialty dermatology.

Multi‑quarter cash runway

A reported cash balance that extends runway into H2 2027 gives management time to complete Phase 3 work and engage regulators without immediate capital raises. This structurally reduces short‑term dilution risk and allows execution on catalyst milestones over the next 12–24 months.

Negative Factors

No recurring revenue

A return to zero revenue demonstrates the company remains pre‑commercial and dependent on clinical outcomes and financing. Without sustainable product sales, long‑term viability hinges on approvals or consistent external funding, increasing execution and financing risk over the medium term.

Persistent cash burn

Ongoing negative operating and free cash flow indicates the company must rely on financings to fund development. Over 2–6 months this structural burn increases dilution and creates uncertainty around the ability to fully fund pivotal trials absent partner deals or capital markets access.

Earnings volatility and quality risk

Large year‑to‑year swings in reported earnings suggest results are driven by non‑operational items and one‑offs rather than stable operations. This undermines visibility for forecasting, complicates capital planning, and raises the probability management must secure dilutive financing if clinical timelines slip.

Palvella Therapeutics Business Overview & Revenue Model

Company Description

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

How the Company Makes Money

Palvella Therapeutics generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company aims to achieve profitability by obtaining regulatory approvals for its therapies and subsequently marketing them to healthcare providers and patients. Revenue streams may include sales of approved drugs, milestone payments, and royalties from licensing agreements. Additionally, strategic partnerships with larger pharmaceutical companies can contribute to earnings by providing funding for research and development, as well as sharing commercialization responsibilities.

Palvella Therapeutics Financial Statement Overview

Summary

Financials reflect a development-stage biotech profile: revenue dropped to $0 in 2023–2024, operating losses persist, and operating/free cash flow remain consistently negative (cash burn continues despite some improvement vs. 2023). The 2024 balance sheet is a positive (no debt and improved equity), but fundamentals still rely heavily on external funding.

Income Statement

Revenue has been highly volatile, dropping to $0 in 2023 and 2024 after $25.9M in 2022 (and higher levels in 2019–2021). Profitability remains weak: 2024 shows a large net loss (-$17.4M) and negative operating profit, following a sharp swing from 2023’s reported net profit ($18.7M) back to losses. Overall, the income profile reflects an early-stage biotech with inconsistent revenue and persistent operating losses, creating elevated earnings quality and visibility risk.

Balance Sheet

The balance sheet appears conservatively levered in the most recent period, with total debt at $0 in 2024 and stockholders’ equity improving to $62.6M (up from negative equity in 2022–2023). Total assets also expanded to $88.2M in 2024. The key weakness is the historical instability in equity (negative in 2022–2023), indicating prior capital structure stress and reliance on financing to sustain operations.

Cash Flow

Cash generation is a clear pressure point: operating cash flow and free cash flow are consistently negative across all years shown, including -$10.8M in 2024 and -$13.7M in 2023. Free cash flow burn improved versus 2023, but it deteriorated versus prior periods (free cash flow growth was -66.3% in 2024). With ongoing cash burn and no offset from sustainable operating inflows, the company remains dependent on external funding to support operations.

Breakdown	TTM	Mar 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	25.90M	31.42M	29.32M
Gross Profit	0.00	0.00	0.00	23.12M	29.05M	29.32M
EBITDA	-19.11M	-13.12M	18.69M	-30.50M	-43.37M	-34.94M
Net Income	-32.95M	-17.43M	18.69M	-33.28M	-45.74M	-37.23M
Balance Sheet
Total Assets	66.94M	88.23M	7.55M	16.52M	153.56M	105.01M
Cash, Cash Equivalents and Short-Term Investments	63.57M	83.60M	7.35M	16.05M	117.76M	70.44M
Total Debt	16.02M	0.00	0.00	0.00	14.89M	16.96M
Total Liabilities	28.25M	25.63M	11.43M	39.70M	102.81M	73.98M
Stockholders Equity	38.68M	62.61M	-3.88M	-23.17M	50.76M	31.03M
Cash Flow
Free Cash Flow	-25.47M	-10.84M	-13.70M	-14.84M	-8.61M	-48.62M
Operating Cash Flow	-25.47M	-10.84M	-13.70M	-14.84M	-7.66M	-45.90M
Investing Cash Flow	0.00	0.00	0.00	0.00	-949.00K	39.21M
Financing Cash Flow	74.17M	87.09M	5.00M	9.57M	59.13M	10.12M

Palvella Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 135.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PVLA, the sentiment is Positive. The current price of 135.02 is above the 20-day moving average (MA) of 91.33, above the 50-day MA of 94.39, and above the 200-day MA of 63.47, indicating a bullish trend. The MACD of 10.15 indicates Negative momentum. The RSI at 70.95 is Negative, neither overbought nor oversold. The STOCH value of 90.88 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PVLA.

Palvella Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TBPH	67 Neutral	$924.77M	32.44	14.03%	―	27.12%	―
TYRA	57 Neutral	$1.78B	-17.72	-34.75%	―	―	-17.01%
MNPR	53 Neutral	$366.24M	-15.94	-26.54%	―	―	-73.48%
TERN	52 Neutral	$4.48B	-40.81	-29.12%	―	―	12.45%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NRIX	51 Neutral	$1.64B	-5.25	-49.63%	―	48.32%	-1.91%
PVLA	49 Neutral	$1.60B	―	―	―	―	―

Palvella Therapeutics Corporate Events

Palvella Highlights QTORIN Rapamycin Progress in New Presentation

On January 29, 2026, Palvella Therapeutics posted a new corporate presentation outlining progress on its late-stage pipeline and highlighting QTORIN 3.9% rapamycin anhydrous gel as a potential first FDA-approved, first-line standard-of-care therapy for both microcystic lymphatic malformations and cutaneous venous malformations, collectively representing more than 100,000 diagnosed U.S. patients and an estimated $1–$3 billion-plus peak U.S. sales opportunity. The company reported that 2025 milestones, including positive Phase 2 data in cutaneous venous malformations and completion of enrollment in the Phase 3 SELVA trial in microcystic lymphatic malformations, have set up a catalyst-rich 2026, with topline Phase 3 data in March 2026, an NDA filing for QTORIN rapamycin in the second half of 2026, and multiple additional QTORIN-based programs entering Phase 2 or pivotal studies as Palvella pursues its vision of an enduring rare disease franchise with 10 or more first-in-disease therapies in late-stage development or on the market.

The most recent analyst rating on (PVLA) stock is a Buy with a $93.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.

Palvella Highlights QTORIN Pipeline and 2026 Growth Outlook

On January 12, 2026, Palvella Therapeutics posted a new corporate presentation outlining the advancement of its late‑stage pipeline, led by QTORIN 3.9% rapamycin anhydrous gel, which it positions as a potential first FDA‑approved, first‑line standard‑of‑care therapy for microcystic lymphatic malformations and cutaneous venous malformations, collectively representing more than 100,000 diagnosed U.S. patients and an estimated $1‑$3 billion‑plus U.S. peak sales opportunity. The company highlighted that 2025 milestones, including positive Phase 2 data in cutaneous venous malformations in December 2025 and full enrollment of the Phase 3 SELVA trial in microcystic lymphatic malformations, have set up a catalyst‑rich 2026, with topline Phase 3 data in March 2026, a targeted U.S. approval in 2027, new QTORIN rapamycin and QTORIN pitavastatin programs, and multiple planned Phase 2 and Phase 3 trials supporting its longer‑term vision of building an enduring rare disease franchise with 10 or more first‑in‑disease therapies in late‑stage development or on the market.

The most recent analyst rating on (PVLA) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.

Palvella Therapeutics Reports Positive Phase 2 Study Results

On December 15, 2025, Palvella Therapeutics announced positive topline results from their Phase 2 TOIVA study of QTORIN™ 3.9% rapamycin anhydrous gel for treating cutaneous venous malformations. The study achieved statistical significance on multiple efficacy endpoints, with 73% of participants showing improvement. These results could impact the company’s operations by advancing discussions with the FDA for Breakthrough Therapy Designation and a Phase 3 pivotal study, potentially positioning Palvella as a leader in addressing this unmet medical need.

The most recent analyst rating on (PVLA) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.

Palvella Therapeutics Reports Q3 2025 Financial Results

Palvella Therapeutics reported its third quarter 2025 financial results and provided a corporate update, highlighting the progress in its rare disease pipeline. The company is advancing its QTORIN rapamycin product candidates, with significant upcoming milestones including the Phase 2 TOIVA trial results for cutaneous venous malformations expected in mid-December 2025 and Phase 3 SELVA trial results for microcystic lymphatic malformations anticipated in the first quarter of 2026. Additionally, Palvella announced the development of QTORIN pitavastatin for disseminated superficial actinic porokeratosis, with a Phase 2 study planned for the second half of 2026. The company also reported cash reserves of $63.6 million as of September 30, 2025, expected to fund operations into the second half of 2027.

The most recent analyst rating on (PVLA) stock is a Buy with a $105.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.

Palvella Therapeutics Unveils QTORIN™ Pitavastatin for DSAP

On November 5, 2025, Palvella Therapeutics announced a new product candidate, QTORIN™ pitavastatin, designed to treat disseminated superficial actinic porokeratosis (DSAP). This announcement marks a significant step as it aims to introduce the first pathogenesis-directed therapy for DSAP, potentially impacting the company’s market position by addressing an unmet medical need for over 50,000 patients in the U.S. The development of QTORIN Pitavastatin is part of Palvella’s broader strategy to innovate in the field of rare dermatological conditions, which could enhance its standing among stakeholders and within the industry.

The most recent analyst rating on (PVLA) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.